Merck & Co., Inc. $MRK Stock Holdings Boosted by Synergy Asset Management LLC

Synergy Asset Management LLC raised its position in shares of Merck & Co., Inc. (NYSE:MRK) by 9.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 37,949 shares of the company’s stock after purchasing an additional 3,127 shares during the quarter. Synergy Asset Management LLC’s holdings in Merck & Co., Inc. were worth $3,004,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Legend Financial Advisors Inc. bought a new position in Merck & Co., Inc. during the 2nd quarter valued at $25,000. Barnes Dennig Private Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. during the 1st quarter valued at $27,000. CBIZ Investment Advisory Services LLC lifted its position in shares of Merck & Co., Inc. by 141.7% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock valued at $34,000 after acquiring an additional 221 shares during the last quarter. MorganRosel Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. during the 1st quarter valued at $36,000. Finally, MJT & Associates Financial Advisory Group Inc. acquired a new stake in shares of Merck & Co., Inc. during the 1st quarter valued at $48,000. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Price Performance

MRK opened at $89.45 on Friday. The stock has a fifty day moving average of $82.78 and a 200-day moving average of $81.73. The firm has a market capitalization of $223.41 billion, a P/E ratio of 13.78, a PEG ratio of 0.93 and a beta of 0.37. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $112.08. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. The company had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Equities analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 7th. Stockholders of record on Monday, September 15th will be issued a $0.81 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.6%. Merck & Co., Inc.’s dividend payout ratio is presently 49.92%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their price objective for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Wells Fargo & Company cut their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 30th. Finally, Morgan Stanley cut their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research report on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $106.41.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.